CD274 and non-small cell lung carcinoma: Through mathematical modeling and NMA, we evaluated the cost-effectiveness of first-line Pembro+Chemo relative to first-line Pembro among metastatic NSCLC patients with PD-L1 expression ≥50% from the US health care sector perspective.